Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Disease Areas › Cancer › UK's NICE Backs Roche's Rozlytrek for Patients With Advanced, ROS1-Positive Lung Cancer

UK's NICE Backs Roche's Rozlytrek for Patients With Advanced, ROS1-Positive Lung Cancer

Jun 15, 2020
|
staff reporter

NEW YORK – The UK's National Institute for Health Care Excellence (NICE) today published a final draft guidance recommending that the National Health Service make entrectinib (Roche's Rozlytrek) available as a treatment for patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC) who have not received previous ROS1 inhibitors.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
27
Featured Webinar

Oncology in the Time of COVID-19: Quantitative Proteomic Analysis of Anti-IL6 Treated Patients

Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Jun
16
Featured Webinar

Precision Oncology in Melanoma Patients Treated with Immunotherapy: Clinical and Technological Perspective

Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.

Jun
18
Featured Webinar

Disparities in Precision Oncology: Identifying Barriers and Moving Toward Solutions

Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019. 

What's Popular?

In Cancer

  1. AACR Study of Eli Lilly's Retevmo Shows Anti-Tumor Activity Across Cancers

  2. Keytruda, Hormone Therapy Combination Benefits Advanced Breast Cancer Subgroup in AACR Study

  3. NCI Director Sharpless Outlines Ideas to Aggressively Lower Cancer Deaths

  4. Oncocyte AACR Data Expands Potential Applications for Immunotherapy Response Predictor

  5. Theseus Pharmaceuticals Emerges from Stealth Mode, Raises $100M in Series B Funding

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.